Intestinal barrier function was prospectively examined in the course of a clinical trial evaluating the efficacy and safety of lisofylline for reducing cytotoxic therapy-induced intestinal epithelial damage-related infectious morbidity in patients receiving standard remission-induction therapy for acute myeloid leukaemia. The absorption and permeation of oral D-Xylose, lactulose and mannitol were measured weekly from baseline until marrow recovery in adult recipients of idarubicin plus cytarabine for untreated acute myeloid leukaemia. These studies were correlated with non-haematologic chemotherapyrelated toxicities reflecting mucosal damage, including nausea, vomiting, stomatitis, diarrhoea, abdominal pain and systemic infection. D-xylose absorption decreased and lactulose:mannitol ratio reflecting intestinal permeability increased from baseline until the second and third week after the beginning of the treatment followed by recovery. These measures correlated with infection rates, nausea, vomiting, diarrhoea and increased blood product utilization. Lisofylline was associated with increased intestinal permeability, nausea, vomiting and infection-related morbidity despite a reduction in the duration of neutropaenia. These surrogates of intestinal barrier function correlated well with clinically important outcomes despite the failure to demonstrate reduced morbidity with lisofylline and represent useful objective outcome measurements for future clinical trials of products for the amelioration of the effects of cytotoxic therapy on the intestinal mucosa.
Introduction
Cytotoxic therapy-induced intestinal epithelial damage is associated with a variety of clinical complications, including oropharyngeal mucositis, abdominal pain, diarrhoea, electrolyte imbalance, bleeding risk, neutropaenic enterocolitis and invasive infection owing to the translocation of endogenous microorganisms colonizing gastrointestinal surfaces. [1] [2] [3] [4] Cytotoxic regimens have differential potentials for producing epithelial damage [5] [6] [7] and invasive infection. 8 Moreover, oral and gastroenterological mucositis adds significantly to the economic burden of cancer chemotherapy. 9 Products to ameliorate cytotoxic therapy-mediated oxidative mucosal damage are currently under development, including growth factors such as interleukin-11 10 and keratinocyte growth factor 11 that stimulate intestinal crypt progenitor cells, agents that scavenge oxygen radicals such as amifostine 10 or block pathways leading to the development of oxidative membrane damage such as lisofylline. 12, 13 The evaluation of drug-related treatment effects have focused primarily on visual estimates of the severity of oropharyngeal mucosa damage and upon nausea, vomiting, abdominal pain and diarrhoea as quantitative surrogates of gastrointestinal damage caudal to the oropharynx using a variety of operator-dependent quantitative and semiquantitative scoring systems. 1 More recently, functional measures of the integrity of the intestinal epithelial barrier using orally administered saccharide or radio-labelled probes have been applied to the study of gastrointestinal mucositis among haematopoietic stem cell transplant recipients 5, 7, [14] [15] [16] [17] and in acute myeloid leukaemia. [18] [19] [20] [21] Intestinal permeability may be reflected by an elevated ratio of the concentration of lactulose to mannitol or rhamnose in fractional urinary excretion studies, 21, 22 carrier-mediated transcellular absorption by the serum level of a five-carbon sugar, D-xylose, 18 and enterocyte mass by serum citrulline levels. 17, 22 There is limited experience using these functional assays as outcome measures for strategies to ameliorate cytotoxic therapyinduced intestinal damage. Accordingly, in the course of a randomized, double-blinded, placebo-controlled trial examining the protective effects of lisofylline, we attempted to temporally correlate standard assessments of clinical mucosal toxicity based upon the National Cancer Institute Common Toxicity Criteria 23 with idarubicin plus cytarabine-induced changes in absorption and permeability and infection in adult patients with newly diagnosed acute myeloid leukaemia undergoing remission-induction.
Patients and methods

Patients
Eligibility criteria included adults aged 18 years or older, newly diagnosed untreated acute myeloid leukaemia, a calculated creatinine clearance of 60 ml/min or more, a total bilirubin and aspartate transaminase of less than twice the upper level of normal, a negative pregnancy test in the case of premenopausal women and informed written consent. No subject had had prior chemotherapy, a history of seizures, central nervous system leukaemia, abnormal cardiac function as measured by gated cardiac acquisition scanning or a positive serological test for human immunodeficiency virus. Haematopoietic growth factors were not prescribed. The trial was sanctioned by the University of Manitoba Committee on the Use of Human Subjects in Research.
Study design
Eligible and consenting patients were randomly allocated using a centralized computer-generated system to receive lisofylline 3 mg/kg intravenously every 6 h or an identical placebo (both supplied by Cell Therapeutics, Seattle, WA, USA) beginning 6 h prior to the first dose of idarubicin on day 1 of induction therapy until myeloid recovery, defined by an increase in the circulating absolute neutrophil count to 40.5 Â 10 9 /l over at least two consecutive days or for 28 days. The study was opened on 12 December 1995 and closed with the last enrolment on 13 October 1999.
Cytotoxic therapy
The remission-induction regimen consisted of cytarabine (100 mg/m 2 infused daily over 24 h as a continuous intravenous infusion on days 1-7) plus idarubicin (12 mg/m 2 daily intravenously on days 1-3).
Supportive care
All subjects were nursed in a high-efficiency particulate airfiltered environment and received anti-bacterial chemoprophylaxis with oral ciprofloxacin (500 mg every 12 h). Oral acyclovir (800 mg every 12 h) was administered to patients who had a positive serologic test for Herpes simplex virus. No anti-fungal prophylaxis was administered. Febrile neutropaenic episodes were managed empirically with piperacillin plus gentamicin in accordance with published guidelines. 24 
Intestinal barrier function
Studies were performed at baseline (before administration of cytotoxic therapy and lisofylline/placebo), then at weekly intervals corresponding to days 7, 14, 21 and 28 until marrow recovery. Following a morning void, fasting subjects received a 100 ml oral solution consisting of D-xylose (5 g), lactulose (2 g) and mannitol (5 g). All urine for the fractional excretion determinations was collected over the next 5 h into pre-weighed plastic containers containing 10% thymol as a preservative. Urinary concentrations of lactulose and mannitol were determined by high-performance liquid chromatography and the lactulose:mannitol ratio was calculated as a measure of small bowel permeability. A lactulose:mannitol ratio of less than our standard upper reference limit of 0.0281 (mean72 s.d.) was considered normal. 25, 26 Small bowel absorption of D-xylose was estimated from a sample of serum collected at a time 1 h after the oral solution was administered for serum D-xylose determinations as described previously. 18 A 1 h serum concentration of p0.6 mmol/l was considered abnormal. Gut-related non-haematological toxicities including nausea, vomiting, diarrhoea, abdominal pain and stomatitis were graded daily using the National Cancer Institute Common Toxicity Criteria. 23 
Analysis
Data collected included patient-related variables (age, sex); disease-related variables (baseline total leucocyte count, absolute neutrophil count, haemoglobin, platelet count; and FrenchAmerican-British classification of acute myeloid leukaemia); the daily leucocyte counts, absolute neutrophil counts, absolute lymphocyte counts, platelet counts and serum haemoglobin; treatment-related variables (the highest weekly National Cancer Institute Common Toxicity scores for nausea, vomiting, stomatitis, abdominal pain and diarrhoea); and infection-related complications classified by standard criteria. 27 Karyotypes were analysed according to whether or not they were unfavourable according to the published criteria. 28 Events for the disease-free survival analysis were defined by relapse, death or failure to enter complete remission (at which time failure was considered to have occurred on day 1). The overall survival analysis was defined from the date of diagnosis to the date of death or date of last follow-up.
The permeability and absorption data, infection rates and the non-haematological toxicities were analysed at each of the time points using repeated measured analyses of variance (ANOVA) on SPSS statistical software, version 13 (SPSS Inc., Chicago, IL, USA) as described previously. 18 Further, SAS software (SAS Institute, Cary, NC, USA) Corr procedure was used for estimating the Spearman correlations. The minimum D-xylose serum levels and maximum lactulose:mannitol ratios and highest grades of non-haematological toxicities observed at baseline and during weeks 1-4 were used for the analysis. A P-value of less than 0.05 was considered to be statistically significant.
Results
The characteristics of the 35 consecutive patients studied are shown by allocation in Table 1 . There were no significant differences with regard to sex, age, morphological subtype of acute myeloid leukaemia, circulating blood cell counts at diagnosis and baseline karyotype. Complete remission was obtained in 21 of 35 patients (60%, 95% confidence interval (CI) 42-76%). Induction deaths occurred in six (17.1%) at a mean of 29.8713.7 days (95% CI 2.9-56.7 days). The overall and disease-free survival times in this cohort were 9.4 (95% CI 3.8-15.1) and 2.6 (95% CI 0-7.2) months, respectively. Patients received a median of 12 units of packed red blood cells and 32 units of random donor platelets during the induction period. The transfusion requirements were similar. Systemic first febrile neutropaenic episodes occurred at a median of day 14 (range day . The median time to myeloid reconstitution was 25 days with a range from 3 weeks to 2 months. Whereas allocation to lisofylline had no impact upon infections overall, the incidence of neutropaenic enterocolitis was higher among lisofylline recipients (Table 1) . Of note, the time to neutrophil recovery was shorter for lisofylline recipients (Table 1) . Table 2 demonstrates the relationships between the lowest serum D-xylose concentrations (malabsorption) and highest lactulose:mannitol ratios (permeability) with the maximal scores for the adverse events. The lowest D-xylose serum levels (greatest malabsorption) were correlated with the infection rate (particularly with bloodstream infections; Spearman's correlation coefficient 0.40267, P ¼ 0.0182; and the infection rate in week 2, Spearman's correlation coefficient À0.331, P ¼ 0.05), stomatitis scores, number of units of packed red blood cells and cumulative doses of morphine. In contrast, greater permeability was correlated with the stomatitis and abdominal pain scores. With the exception of the correlations with maximal stomatitis scores, the patterns of scores differed between the absorption and permeability tests. In addition to damage to the upper intestinal absorptive function, maximal infection rates were correlated with stomatitis (Spearman's correlation coefficient 0.46533, P ¼ 0.0049), vomiting (Spearman's correlation coefficient 0.28663, P ¼ 0.095), diarrhoea (Spearman's correlation coefficient 0.44677, P ¼ 0.0071), neutropaenic enterocolitis (Spearman's correlation coefficient 0.5268, P ¼ 0.0011) and cumulative doses of morphine (Spearman's correlation coefficient 0.4808, P ¼ 0.0035). It is of note that neither neutropaenic enterocolitis nor diarrhoea, processes associated with injury to columnar epithelial surfaces of the small and large bowel, were correlated with stomatitis (Spearman's correlation coefficients 0.14832, P ¼ 0.395 and 0.053, P ¼ 0.761, respectively), a process associated with stratified squamous epithelial injury, suggesting that these processes were independent of one another. Moreover, neither D-xylose serum levels nor the lactulose:mannitol ratios were correlated with the neutrophil nadir (Spearman's correlation coefficients 0.14804 and 0.06905, respectively, P ¼ 0.4034 and P ¼ 0.698, respectively), also suggesting that intestinal cytotoxicity and myelotoxicity were independent processes. Lisofylline recipients had more grade 1-4 nausea (15 of 16 versus 11 of 19, P ¼ 0.016), vomiting Table 3 demonstrates the temporal relationships for the major variables of interest from baseline until the end of week 4 (day 28). The highest lactulose:mannitol ratios and lowest serum D-xylose levels were observed at day 14 (week 2, Spearman's correlation coefficient, À0.492, P ¼ 0.003). Infection rates, malabsorption, permeability, blood product utilization and toxicity scores were maximal between days 14 and 21, times correlated with the neutrophil nadir, the median time to bloodstream infection and to the development of neutropaenic enterocolitis (Table 1) . Figures 1 and 2 illustrate the effect of allocation on the permeability and absorption profiles, respectively, over the time course of the study. Despite greater baseline malabsorption among placebo recipients (Figure 2 , mean difference 0.21, 95% CI 0.05-0.37), allocation to lisofylline was associated with greater permeability (Figure 1 ) and malabsorption ( Figure 2 ) at days 14 and 21 (P ¼ 0.044 and P ¼ 0.054, respectively, repeated measures analysis of variance (ANOVA)).
Discussion
Tissues have differing responses to cytotoxic injury. Temporal discordances in the development of oral and gastrointestinal Table 2 Correlation of minimum D-xylose serum levels (absorption) and maximum lactulose:mannitol ratios (permeability) with maximum number of adverse events in patients undergoing remission-induction therapy for acute myeloid leukaemia (Spearman's correlation coefficients) Table 3 Temporal relationship of D-xylose absorption and lactulose:mannitol ratio permeability profiles and the incidence of systemic infection, blood product utilization and non-haematologic gut-related toxicities Staphylococcus aureus cellulitis; community-acquired pneumonia. c Candida albicans pseudomembranous pharyngitis on day +4 (2), day +5 (1) and day +7 (1). C. albicans pyonephrosis on day +4 (1).
d
Bloodstream infections (n ¼ 5): coagulase-negative Staphylococci (n ¼ 2, days +11), viridans group Streptococcus spp plus Micrococcus spp (n ¼ 1, day +13), C. albicans day +14, C. albicans day +13 with subsequent hepatosplenic fungal infection (HSFI) day +31; non-bacteremic microbiologically documented infections (n ¼ 5): C. albicans pseudomembranous pharyngitis (n ¼ 4, days +9, +10, +10, +12), C. albicans oesophagitis (n ¼ 1, day +12); clinically documented infections (n ¼ 13): oral mucositis (n ¼ 3, days +8, +9, +9), oesophagitis (n ¼ 1, day +9) pneumonia (n ¼ 3, days +8, +9, +12), central venous catheter exit site infection (n ¼ 1, day +9) and tunnel site infection (n ¼ 1, day +11), left knee cellulites (n ¼ 1, day +9), neutropaenic enterocolitis (n ¼ 3, days +14); unexplained fevers (n ¼ 9): days +8, +9, +10 (2), +13 (2) and +14 (3), respectively. e Bloodstream infections (n ¼ 5): coagulase-negative Staphylococcus (day +16), Diphtheroidal bacteraemia (day +18), Enterococcus faecalis bacteraemia (day +18) with persistent bacteraemia (day +23) and secondary E. faecalis left psoas abscess (day +24), C. albicans fungaemia (day +17) with pulmonary nodules (day +16) and HSFI (day +26), C. tropicalis fungaemia (day +16) with C. tropicalis skin nodules (day +16) and HSFI (day +19); non-bacteraemic microbiologically documented infections (n ¼ 1): respiratory syncytial virus pneumonia day +16; clinically documented infections (n ¼ 17): oral mucositis day +15, right-sided hordeoleum day +18, cellulites of the scalp day +18, central venous catheter-related softtissue infections day +16, abscess left fourth finger day +19, submandibular lymphadenitis day +15, axillary lymphadenitis day +16, pneumonia (n ¼ 4, days +15, +15, +16, +20), neutropaenic enterocolitis (n ¼ 6, days +17, +17, +17, +17, +18, +19); unexplained fevers (n ¼ 4): days +15, +16, +17, +21. f Bloodstream infections (n ¼ 3): S. epidermidis bacteraemia (day +26); E. faecium plus diphtheroid (day +25); C. albicans fungaemia (day +25) with skin nodules (day +21); non-bacteremic microbiologically documented infections (n ¼ 1): coagulase-negative Staphylococcal central venous catheter-related bacteremia day +28; clinically documented infections (n ¼ 1): left lower lobe pneumonia day +25. g National Cancer Institute Common Toxicity criteria. 23 mucositis may be a function of differing susceptibilities of the squamous epithelial surfaces of the oropharynx and simple nonstratified epithelial surfaces of the small and large bowel to cytotoxic injury, respectively. 1, 29 The integrity of the oropharyngeal mucosa does not necessarily predict the state of distal tissues. 29 Our observations on a relatively small sample confirming previous reports 7, [15] [16] [17] 21 are consistent with this hypothesis. In addition, our observations further re-enforce the independence of the chemotherapy-induced intestinal cytotoxicity and myelotoxicity.
The serial absorption and permeability studies in this report permitted the detection of potentially deleterious effects of an agent hypothesized to ameliorate cytotoxic therapy-induced mucosal damage. We, as others, 30, 31 observed more gastrointestinal toxicity, including nausea, vomiting and diarrhoea among lisofylline recipients. This, however, was associated with increased intestinal permeability which, in turn correlated with increased mucosal barrier damage (stomatitis) and increased infection rates, particularly bloodstream infections and neutropaenic enterocolitis. The increased permeability and incidence of neutropaenic enterocolitis among lisofylline recipients are of concern and suggest a treatment-related effect on the intestinal mucosa not heretofore recognized. It is possible that the differential effect of lisofylline upon permeability and absorption noted in Figures 1 and 2 may reflect delayed repair of tight junctional integrity rather than epithelial restitution, a process that does not require cell proliferation. 32 Despite earlier encouraging reports, 12, 13, 31 the results of this study, like others, 30 do not support a role for lisofylline in ameliorating cytotoxic therapy-induced intestinal mucosal injury.
There are a number of limitations to this study, including the small sample size, the relatively long period over which consecutive patients were accrued and the limited number of physiological measurements used to assess intestinal barrier function.
This was a single centre study. The sample was accrued over 46 months and reflected the rate at which patients with acute myeloid leukaemia were referred to our centre. A larger sample may have permitted more robust relationships to be detected. For example, the double-blinded study design and the randomization process should have allowed for an even distribution of factors that could influence the baseline absorption parameters; however, our sample size may have been too small to filter out random variances. Accordingly, we were unable to identify baseline patient-or disease-related factors to explain the disparity in baseline serum D-xylose levels by allocation ( Figure 2) .
The probes used in this study utilize differing mechanisms for passing across intestinal mucosal surfaces and only reflect small bowel function as they are all degraded by colonic bacteria. D-Xylose is actively absorbed from the small bowel using a carriermediated mechanism, whereas the lactulose:mannitol ratio reflects the integrity of small intestinal tight junction complexes normalized to intestinal surface area. 26 Although we were able to detect a significant lisofylline-related effect upon permeability, the effect upon xylose absorption was less dramatic. The use of additional probes such as sucrose, 33, 34 radio-labelled ethylenaminediamine tetraacetic acid, 15, 16 rhamnose, 21 O-methylglucose, 22 citrulline 17, 22 or sucralose [34] [35] [36] might have enhanced the sensitivity for detecting differential treatment effects. Used concurrently, these probes offer the potential to study the differential site-specific damaging effects of cytotoxic therapy on the gastrointestinal mucosa.
Our results demonstrate the value of using physiological measures of intestinal barrier function in the design of clinical trials evaluating products such as palifermin, 11 amifostine 10 or even immunoglobulin 16 for the amelioration of cytotoxic therapy-induced intestinal barrier dysfunction and mucositis. It may be prudent to consider the inclusion of these measurements as secondary outcomes in future trials to complement the information provided by more traditional oral and intestinal mucositis scoring systems. represents original research designed and conducted by EJB. JBM collaborated on the intestinal permeability studies. The results of this study have not been previously presented or published. Interpretation of the study results and discussions regarding publication were made by the investigators without participation of the sponsor. The protocol was approved by the Committee on Use of Human Subjects in Research, the University of Manitoba. All patients provided informed written consent.
